New cocktail of drugs takes on tough pancreatic cancer
NCT ID NCT07445295
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase III trial is testing whether adding the experimental drug chiauranib and an immunotherapy (toripalimab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 558 participants will be randomly assigned to receive either the full combo or chemo plus placebos. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chiauranib, toripalimab, albumin-paclitaxel, gemcitabine
What this could lead to
If successful, this combination could become a new first-line treatment option for metastatic pancreatic cancer, potentially improving survival and disease control.
What could go wrong
This is an early-stage Phase III trial with no results yet. The added drugs may increase side effects without improving outcomes, and pancreatic cancer is notoriously hard to treat.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••